This multi-target design represents a significant advance beyond both the single-agonist GLP-1 receptor agonists (such as semaglutide) and the dual GIP/GLP-1 agonists (such as tirzepatide)
Im not at my goal weight yet but Im getting closer
If you have been diagnosed with diabetes, speak with your healthcare provider about switching to Mounjaro which contains the same active ingredient as Zepbound (tirzepatide) and is approved for type 2 diabetes
Efficacy: Wegovy vs
1 3 2 1 2 GIPGLP-12 [1] 2[1] 20234 2.5mg415mg[1] GLP-1[2] GLP-1 [2] 1 0.25mg40.5mg1.0mg[2] GIP+GLP-1GLP-1 GLP-1 GLP-1GIP [1][2] GIP GLP-1 SURPASS-2SURMOUNT-5 21,879SURPASS-2 4015mg11.2kg 1mg5.7kg [3] SURMOUNT-57220.2%13.7%[4] 15mg9.5kg[5] 23 2.5mg5mg 0.25mg0.51.0mg 246[3][4] [1][2] GLP-1 24 1620%1822%[6] GIPGLP-1 [1] GLP-1 [1][2] 1 2 2.5mg120,00030,0005mg30,00055,000 2.0mg1420,00025,000 10mg150,000 2 [1][2] 35mg14,6001.0mg6,500 2.5mg11,9245mg13,848[1] 1 1 2.5mg45mg7.5mg10mg12.5mg15mg6 [1] 0.25mg40.5mg41.0mg3[2] [1] [2] GLP-1 2 1[7] 15mg9.5kg1.0mg4.4kg14mg2.6kg[5] 110,00030,000 30[7] GIPGLP-120% BMI [4] 2.5mg15mg6 GLP-1 2 [1][2] Q1
Pick a shorter iFIT session, follow your iFIT Trainer, and count the day as complete